You just read:

Data Published in The Lancet Oncology Suggest CyberKnife® Prostate Patients Experienced Lower Levels of Acute Genitourinary Toxicity (Grade 2 or Higher) Than Patients Treated on a Conventional Linear Accelerator

News provided by

Accuray Incorporated

Sep 17, 2019, 18:30 ET